Similarly, on the basis of the Keynote-091 study [17], a programmed cell death 1 (PD-1) inhibitor, pembrolizumab, has been approved for the adjuvant treatment of NSCLC stages IB-IIIA. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.